Body Signal Integration Training: A Case Series

November 13, 2023 updated by: Krishna Panchmatia, University of Manchester

Feasibility and Acceptability of Body Signal Integration Training for Functional Neurological Disorder: A Case Series

The goal of this clinical trial is to learn about an intervention package in individuals with Functional Neurological Disorder (FND). The main questions it aims to answer are:

  • Is the intervention package acceptable to and feasible to deliver to individuals with FND?
  • Does the intervention package improve symptoms of FND?

Participants will be asked to engage in 8 weekly sessions of an intervention aimed to improve the perception of signals coming from the body (interoception). Participants will be asked to complete tasks between session practising tuning into signals from the body. Participants will also be asked to complete questionnaires measuring their psychological wellbeing, FND symptoms and interoception.

Study Overview

Status

Active, not recruiting

Detailed Description

The designed intervention is derived from the Integrative Cognitive Model (ICM) of medically unexplained symptoms and Psychogenic Non-Epileptic Seizures, (Brown, 2004; Ven den Bergh, Witthoft, Petersen, & Brown, 2017; Brown & Reuber, 2016). This model suggests that conscious body perceptions are interpretations of bottom-up signals influenced by top-down factors such as attention, beliefs, fears and emotional states. The model suggests that Functional Neurological Disorders are distortions in body awareness that arise when normal bodily signals are misinterpreted as noxious, due to a combination of top-down factors and the bodily signals themselves being weak. The proposed intervention targets several factors identified as important in this model, including imprecise bodily signals, poor emotion recognition and regulation, anxious beliefs and fears about symptoms and symptom-focussed processing. The intervention aims to sharpen signals from the body by reducing avoidance and misinterpretation of those signals and thereby improve body perception and interoceptive accuracy. If acceptable, feasible and effective, the proposed intervention would contribute to the literature for the Integrative Cognitive Model of FND and inform future interventions for individuals with FND.

Participants will be offered 8, 1-hour, online sessions, delivered weekly via Microsoft Teams. The psychological intervention will focus on developing skills to improve attunement to the signals from the body to the brain.

  • The sessions will involve engaging in various exercises tuning into the body under different circumstances. Participants will be asked to tune into how particular objects feel in their hands. Participants may be presented with images or scenarios to make them feel a little happy or sad and then will be asked to tune into how the body feels in response to them.
  • Participants will be asked to complete weekly measures online via Qualtrics survey, they will be asked to do this in the 10-15 minutes prior to their session commencing.
  • A full manual of the intervention plan will be uploaded to documents.
  • Following the final session of treatment, a date to complete a one-month follow up will be arranged with the participant.

Follow-Up:

  • One month following the end of psychological therapy, a session will be attended remotely via Microsoft Teams by participants.
  • During this session, all pre-treatment, weekly and post-treatment measures will be re-administered including questionnaires measuring satisfaction with therapy.

Study Type

Interventional

Enrollment (Actual)

8

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Manchester, United Kingdom, M13 9NT
        • Krishna Panchmatia

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Currently experiencing FND symptoms, as measured on items 34-47 on the SOMS-7 (excluding seizures and hallucinations). The study is aiming to investigate the feasibility of an intervention for individuals with FND.
  • Confirmation of diagnosis of FND (through letter from medical doctor) to ensure participants have a diagnosis of FND and are therefore the target audience for the intervention
  • Willing and able to participate in remote therapy. The intervention will be delivered remotely so participants must be willing to engage with remote therapy.
  • Able to converse in English proficiently without support from a link worker. The study will not be using interpreters and so an ability to converse proficiently in English to be able to engage with the intervention is needed.
  • Residing in the UK for the duration of the study, this is in order to develop crisis and risk management plans for participants should they experience any negative effects from therapy or any risks be expressed throughout the course of the intervention.

Exclusion Criteria:

  • Currently undergoing any other psychological therapy
  • Previous experience of a mindfulness-based intervention targeting FND.
  • Individuals with symptoms of epilepsy and loss of consciousness.
  • Symptoms of psychosis (as assessed on the Comprehensive Assessment of At-Risk Mental State, CAARMS).
  • Diagnosis of any type of Personality Disorder
  • Active plans of self-harm and/or suicide. Potential participants will be asked to complete the risk items on the CORE-OM and will be interviewed around these. This is to ensure the safety of participants engaging in novel therapy and to manage the risks of any potential adverse side-effects of therapy
  • History of prior suicide attempts, to manage the risks of causing negative side effects of therapy
  • Any difficulties with alcohol or substance misuse.
  • Individuals with active symptoms of Post Traumatic Stress Disorder (PTSD) i.e., having current symptoms of nightmares and flashbacks.
  • Individuals with symptoms of an eating disorder.

Rationale for exclusion criteria is described in the study protocol

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention
Full session plan of the 8 sessions is uploaded to documents. This arm will consist of weekly 1 hour 1:1 sessions with Trainee Clinical Psychologist doing exercises aimed at improving interoception. Exercises will include tuning into the body under different circumstances e.g., while having a drink, looking at pictures to induce a positive mood state.
Information and protocol uploaded to documents.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of participants that complete 80% of the intervention
Time Frame: 8 weeks (span of intervention delivery)
This is a measure of adherence, feasibility and acceptability of the intervention. 80% of participants attending 80% of sessions offered will be considered acceptable adherence
8 weeks (span of intervention delivery)
Number of participants rating the therapy as acceptable on questionnaire of therapy satisfaction
Time Frame: 8 weeks (span of intervention delivery)
Measure of acceptability of intervention
8 weeks (span of intervention delivery)
Number of serious adverse reactions as evidenced by significant increase in distress or symptom rating on Euroqol Health Questionnaire (EQ5D), Clinical Outcomes in Routine Evaluation (CORE-10) or FND questionnaire
Time Frame: 8 weeks (span of the intervention delivery)
Number of serious adverse reactions will be a measure of feasibility and acceptability of the intervention
8 weeks (span of the intervention delivery)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of participants showing a 30% reliable change reduction in Core FND symptoms as measured by Screening for Somatic Symptom Disorders (SOMS-7) and FND questionnaire
Time Frame: Approximately 3 months - measure will be from baseline measure completion to end of therapy
Measure of treatment efficacy
Approximately 3 months - measure will be from baseline measure completion to end of therapy
Rate of Change and Clinically Significant Change of Interoception as measured by Multidimensional Assessment of Interoceptive Awareness
Time Frame: Approximately 3 months - measure will be from baseline completion until end of therapy
Measure of treatment efficacy in improving interoception
Approximately 3 months - measure will be from baseline completion until end of therapy

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Krishna Panchmatia, University of Manchester

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 19, 2023

Primary Completion (Estimated)

January 1, 2024

Study Completion (Estimated)

February 1, 2024

Study Registration Dates

First Submitted

July 3, 2023

First Submitted That Met QC Criteria

July 3, 2023

First Posted (Actual)

July 12, 2023

Study Record Updates

Last Update Posted (Actual)

November 14, 2023

Last Update Submitted That Met QC Criteria

November 13, 2023

Last Verified

November 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Functional Neurological Disorder

Clinical Trials on Body Signal Integration Training

Subscribe